Biogen
Biogen, founded in 1978 and based in Cambridge, Massachusetts, develops and manufactures medicines for neurological and other challenging diseases, including multiple sclerosis, Alzheimer's, ALS and rare diseases.
Biogen is one of the world's first global biotechnology companies. Founded in 1978 and headquartered in Cambridge, Massachusetts, it develops and manufactures medicines for patients with neurological and other challenging diseases, drawing on research into human biology and on capabilities in biologics manufacturing. Its stated ambition is to turn scientific breakthroughs into first-in-class treatments.
The company's disease focus areas span neurology, immunology and rare diseases. Its portfolio includes therapies for multiple sclerosis, Alzheimer's disease, amyotrophic lateral sclerosis (ALS), spinal muscular atrophy, lupus and postpartum depression. Work across drug discovery and development runs alongside large-scale manufacturing operations in Research Triangle Park, North Carolina.
Biogen employs close to 2,500 people in research and development in the United States and more than 1,500 in manufacturing in North Carolina, within a global workforce and operations that extend to communities worldwide. After nearly 50 years in operation, the company continues to combine scientific expertise with a commitment to patients and to creating value for shareholders and the communities in which it operates.
The company describes its culture by the motto "Caring Deeply. Working Fearlessly. Changing Lives™", reflecting a stated emphasis on rigorous science, courage in taking bold risks and a commitment to patients.